UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Larotrectinib efficacy and safety in TRK fusion cancer: An expanded clinical dataset showing consistency in an age and tumor agnostic approach

Annals of oncology, 2018-11, Vol.29, p.ix23-ix23

2018

Volltextzugriff (PDF)

The management of hepatocellular carcinoma. Current expert opinion and recommendations derived from the 10th World Congress on Gastrointestinal Cancer, Barcelona, 2008

Annals of oncology, 2009-06, Vol.20 (suppl-7), p.vii1-vii6

2009

Volltextzugriff (PDF)

Sacituzumab govitecan, a Trop-2-directed antibody-drug conjugate, for patients with epithelial cancer: final safety and efficacy results from the phase I/II IMMU-132-01 basket trial

Annals of oncology, 2021-06, Vol.32 (6), p.746-756

2021

Volltextzugriff (PDF)

2309P High DDR1 mRNA and protein expression across human tumor types correlate with epithelial composition of the tumor microenvironment

Annals of oncology, 2023-10, Vol.34, p.S1180-S1180

2023

Volltextzugriff (PDF)

665P Safety, PK, immune activation, and clinical outcomes with RBS2418 treatment, an oral ENPP1 inhibitor, alone or in combination with pembrolizumab in advanced solid tumors

Annals of oncology, 2024-09, Vol.35, p.S523-S523

2024

Volltextzugriff (PDF)

608O Preliminary safety and clinical activity of ASP3082, a first-in-class, KRAS G12D selective protein degrader in adults with advanced pancreatic (PC), colorectal (CRC), and non-small cell lung cancer (NSCLC)

Annals of oncology, 2024-09, Vol.35, p.S486-S487

2024

Volltextzugriff (PDF)

1079TiP A phase I first-in-human study of PRTH-101, an IgG1 monoclonal antibody targeting DDR1, as a monotherapy and combined with pembrolizumab in patients with advanced solid malignancies

Annals of oncology, 2023-10, Vol.34, p.S649-S650

2023

Volltextzugriff (PDF)

1039P First-in-human phase I study of givastomig, a novel Claudin 18.2/4-1BB bispecific antibody in advanced solid tumors

Annals of oncology, 2023-10, Vol.34, p.S631-S631

2023

Volltextzugriff (PDF)

463P Efficacy and safety of larotrectinib in a pooled analysis of patients (Pts) with tropomyosin receptor kinase (TRK) fusion cancer with an extended follow-up

Annals of oncology, 2022-09, Vol.33, p.S751-S752

2022

Volltextzugriff (PDF)

354P NUC-3373, a ProTide transformation of 5-FU, in combination with oxaliplatin (NUFOX) or irinotecan (NUFIRI) in patients with advanced colorectal cancer (CRC) (NuTide:302)

Annals of oncology, 2022-09, Vol.33, p.S697-S698

2022

Volltextzugriff (PDF)

A Phase I Study of Cetuximab in Combination with Gemcitabine and Radiation for Locally Advanced Pancreatic Cancer

International journal of radiation oncology, biology, physics, 2008, Vol.72 (1), p.S250-S251

2008

Volltextzugriff (PDF)

612P - SPICE, a phase I study of enadenotucirev in combination with nivolumab in tumours of epithelial origin: Analysis of the metastatic colorectal cancer patients in the dose escalation phase

Annals of oncology, 2019-10, Vol.30, p.v231-v231

2019

Volltextzugriff (PDF)

SPICE, a phase I study of enadenotucirev in combination with nivolumab in tumours of epithelial origin: Analysis of the metastatic colorectal cancer patients in the dose escalation phase

Annals of oncology, 2019-10, Vol.30, p.v231

2019

Volltextzugriff (PDF)

Larotrectinib efficacy and safety in TRK fusion cancer: An expanded clinical dataset showing consistency in an age and tumor agnostic approach

Annals of oncology, 2018-10, Vol.29 Suppl 8, p.viii133

2018

Volltextzugriff (PDF)

682P - Phase III, international, multicenter, randomized, open-label trial of adjuvant nab-paclitaxel plus gemcitabine (nab-P/G) vs gemcitabine (G) alone for surgically resected pancreatic adenocarcinoma (APACT): Subgroup analyses

Annals of oncology, 2019-10, Vol.30, p.v259-v260

2019

Volltextzugriff (PDF)

Durability of response with larotrectinib in adult and pediatric patients with TRK fusion cancer

Annals of oncology, 2019-10, Vol.30, p.v162-v163

2019

Volltextzugriff (PDF)

445PD - Durability of response with larotrectinib in adult and pediatric patients with TRK fusion cancer

Annals of oncology, 2019-10, Vol.30, p.v162-v163

2019

Volltextzugriff (PDF)

Phase III, international, multicenter, randomized, open-label trial of adjuvant nab-paclitaxel plus gemcitabine (nab-P/G) vs gemcitabine (G) alone for surgically resected pancreatic adenocarcinoma (APACT): Subgroup analyses

Annals of oncology, 2019-10, Vol.30, p.v259-v260

2019

Volltextzugriff (PDF)

Eltanexor (KPT-8602), a second-generation selective inhibitor of nuclear export (SINE) compound, in patients with metastatic colorectal cancer (mCRC)

Annals of oncology, 2018-10, Vol.29, p.viii716-viii716

2018

Volltextzugriff (PDF)

Results of a phase I study of andecaliximab in combination with mFOLFOX6 and bevacizumab in patients with previously untreated metastatic colorectal cancer

Annals of oncology, 2018-10, Vol.29, p.viii189-viii190

2018

Volltextzugriff (PDF)

A phase I study to evaluate the safety, pharmacokinetics, and pharmacodynamics of PF-06939999 (PRMT5 inhibitor) in patients with selected advanced or metastatic tumors with high incidence of splicing factor gene mutations

ESMO open, 2024-04, Vol.9 (4), p.102961-102961, Article 102961

2024

Volltextzugriff (PDF)

The management of locally advanced pancreatic cancer: European Society of Digestive Oncology (ESDO) expert discussion and recommendations from the 14th ESMO/World Congress on Gastrointestinal Cancer, Barcelona

Annals of oncology, 2014-06, Vol.25, p.ii1-ii4

2014

Volltextzugriff (PDF)

297 POSTER Phase I and pharmacokinetic trial of SJG-136 administered on a daily × 5 schedule

European journal of cancer supplements, 2006-11, Vol.4 (12), p.93-93

2006

Volltextzugriff (PDF)

Root vascular bundle arrangements among cotton strains and cultivars

Environmental and experimental botany, 1985-01, Vol.25 (1), p.23-30

1985

Volltextzugriff (PDF)

1 – 25 von 113

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(107)
Mit Volltextzugriff
(102)

Publikationsform

Artikel
(112)
Bücher
(1)

Sprache

Englisch
(112)
Deutsch
(1)

Erscheinungsjahr

n.n

Thema

Science & Technology
(57)
Life Sciences & Biomedicine
(34)
Particle Physics
(21)
Physical Sciences
(21)
Physics
(21)
Physics, Particles & Fields
(19)
Urology & Nephrology
(12)
Oncology
(11)
Biological And Medical Sciences
(10)
Humans
(10)
Male
(10)
Prostate Cancer
(9)
Plant Sciences
(8)
Epidermal Cells
(7)
Fundamental And Applied Biological Sciences. Psychology
(7)
Animals
(6)
Cell Walls
(5)
Aged
(4)
Agronomy. Soil Science And Plant Productions
(4)
Cotton Fibers
(4)

15 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

5 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 90 Tagen
(2)

Menü

Weitere Dienste

Einstellungen

Larotrectinib efficacy and safety in TRK fusion cancer: An expanded clinical dataset showing consistency in an age and tumor agnostic approach

The management of hepatocellular carcinoma. Current expert opinion and recommendations derived from the 10th World Congress on Gastrointestinal Cancer, Barcelona, 2008

Sacituzumab govitecan, a Trop-2-directed antibody-drug conjugate, for patients with epithelial cancer: final safety and efficacy results from the phase I/II IMMU-132-01 basket trial

2309P High DDR1 mRNA and protein expression across human tumor types correlate with epithelial composition of the tumor microenvironment

665P Safety, PK, immune activation, and clinical outcomes with RBS2418 treatment, an oral ENPP1 inhibitor, alone or in combination with pembrolizumab in advanced solid tumors

608O Preliminary safety and clinical activity of ASP3082, a first-in-class, KRAS G12D selective protein degrader in adults with advanced pancreatic (PC), colorectal (CRC), and non-small cell lung cancer (NSCLC)

1079TiP A phase I first-in-human study of PRTH-101, an IgG1 monoclonal antibody targeting DDR1, as a monotherapy and combined with pembrolizumab in patients with advanced solid malignancies

1039P First-in-human phase I study of givastomig, a novel Claudin 18.2/4-1BB bispecific antibody in advanced solid tumors

463P Efficacy and safety of larotrectinib in a pooled analysis of patients (Pts) with tropomyosin receptor kinase (TRK) fusion cancer with an extended follow-up

354P NUC-3373, a ProTide transformation of 5-FU, in combination with oxaliplatin (NUFOX) or irinotecan (NUFIRI) in patients with advanced colorectal cancer (CRC) (NuTide:302)

A Phase I Study of Cetuximab in Combination with Gemcitabine and Radiation for Locally Advanced Pancreatic Cancer

612P - SPICE, a phase I study of enadenotucirev in combination with nivolumab in tumours of epithelial origin: Analysis of the metastatic colorectal cancer patients in the dose escalation phase

SPICE, a phase I study of enadenotucirev in combination with nivolumab in tumours of epithelial origin: Analysis of the metastatic colorectal cancer patients in the dose escalation phase

Larotrectinib efficacy and safety in TRK fusion cancer: An expanded clinical dataset showing consistency in an age and tumor agnostic approach

682P - Phase III, international, multicenter, randomized, open-label trial of adjuvant nab-paclitaxel plus gemcitabine (nab-P/G) vs gemcitabine (G) alone for surgically resected pancreatic adenocarcinoma (APACT): Subgroup analyses

Durability of response with larotrectinib in adult and pediatric patients with TRK fusion cancer

445PD - Durability of response with larotrectinib in adult and pediatric patients with TRK fusion cancer

Phase III, international, multicenter, randomized, open-label trial of adjuvant nab-paclitaxel plus gemcitabine (nab-P/G) vs gemcitabine (G) alone for surgically resected pancreatic adenocarcinoma (APACT): Subgroup analyses

Eltanexor (KPT-8602), a second-generation selective inhibitor of nuclear export (SINE) compound, in patients with metastatic colorectal cancer (mCRC)

Results of a phase I study of andecaliximab in combination with mFOLFOX6 and bevacizumab in patients with previously untreated metastatic colorectal cancer

A phase I study to evaluate the safety, pharmacokinetics, and pharmacodynamics of PF-06939999 (PRMT5 inhibitor) in patients with selected advanced or metastatic tumors with high incidence of splicing factor gene mutations

The management of locally advanced pancreatic cancer: European Society of Digestive Oncology (ESDO) expert discussion and recommendations from the 14th ESMO/World Congress on Gastrointestinal Cancer, Barcelona

The management of metastatic pancreatic cancer: expert discussion and recommendations from the 14th ESMO/World Congress on Gastrointestinal Cancer, Barcelona, 2012

297 POSTER Phase I and pharmacokinetic trial of SJG-136 administered on a daily × 5 schedule

Root vascular bundle arrangements among cotton strains and cultivars

Suchergebnisse filtern